Rebecca R. Roberts
Rush University Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Rebecca R. Roberts.
Clinical Infectious Diseases | 2009
Rebecca R. Roberts; Bala Hota; Ibrar Ahmad; R. Douglas Scott; Susan Foster; Fauzia Abbasi; Shari Schabowski; Linda M. Kampe; Ginevra G. Ciavarella; Mark Supino; Jeremy Naples; Ralph L. Cordell; Stuart B. Levy; Robert A. Weinstein
BACKGROUND Organisms resistant to antimicrobials continue to emerge and spread. This study was performed to measure the medical and societal cost attributable to antimicrobial-resistant infection (ARI). METHODS A sample of high-risk hospitalized adult patients was selected. Measurements included ARI, total cost, duration of stay, comorbidities, acute pathophysiology, Acute Physiology and Chronic Health Evaluation III score, intensive care unit stay, surgery, health care-acquired infection, and mortality. Hospital services used and outcomes were abstracted from electronic and written medical records. Medical costs were measured from the hospital perspective. A sensitivity analysis including 3 study designs was conducted. Regression was used to adjust for potential confounding in the random sample and in the sample expanded with additional patients with ARI. Propensity scores were used to select matched control subjects for each patient with ARI for a comparison of mean cost for patients with and without ARI. RESULTS In a sample of 1391 patients, 188 (13.5%) had ARI. The medical costs attributable to ARI ranged from
Clinical Infectious Diseases | 2003
Rebecca R. Roberts; R. Douglas Scott; Ralph L. Cordell; Steven L. Solomon; Lynn Steele; Linda M. Kampe; William E. Trick; Robert A. Weinstein
18,588 to
Medical Care | 2010
Rebecca R. Roberts; R. Douglas Scott; Bala Hota; Linda M. Kampe; Fauzia Abbasi; Shari Schabowski; Ibrar Ahmad; Ginevra G. Ciavarella; Ralph L. Cordell; Steven L. Solomon; Reidar Hagtvedt; Robert A. Weinstein
29,069 per patient in the sensitivity analysis. Excess duration of hospital stay was 6.4-12.7 days, and attributable mortality was 6.5%. The societal costs were
Annals of Emergency Medicine | 1997
Robert J. Rydman; Robert J Zalenski; Rebecca R. Roberts; Gary A Albrecht; Virginia M. Misiewicz; Linda M. Kampe; Madeline McCarren
10.7-
Medical Care | 1998
Robert J. Rydman; Miriam L. Isola; Rebecca R. Roberts; Robert J. Zalenski; Michael F. McDermott; Daniel G. Murphy; Madeline McCarren; Linda M. Kampe
15.0 million. Using the lowest estimates from the sensitivity analysis resulted in a total cost of
Journal of Medical Systems | 1999
Jeffrey Schaider; Samson Ngonyani; Stephen Tomlin; Robert J. Rydman; Rebecca R. Roberts
13.35 million in 2008 dollars in this patient cohort. CONCLUSIONS The attributable medical and societal costs of ARI are considerable. Data from this analysis could form the basis for a more comprehensive evaluation of the cost of resistance and the potential economic benefits of prevention programs.
Clinical Infectious Diseases | 2008
Frederick J. Angulo; Lyn James; Rebecca R. Roberts; Roderick C. Jones; John T. Watson; Bala Hota; Linda M. Kampe; Robert A. Weinstein; Susan I. Gerber
Hospital-associated infection is well recognized as a patient safety concern requiring preventive interventions. However, hospitals are closely monitoring expenditures and need accurate estimates of potential cost savings from such prevention programs. We used a retrospective cohort design and economic modeling to determine the excess cost from the hospital perspective for hospital-associated infection in a random sample of adult medical patients. Study patients were classified as being not infected (n=139), having suspected infection (n=8), or having confirmed infection (n=17). Severity of illness and intensive unit care use were both independently associated with increased cost. After controlling for these confounding effects, we found an excess cost of
Interfaces | 2009
Reidar Hagtvedt; Paul M. Griffin; Pinar Keskinocak; Rebecca R. Roberts
6767 for suspected infection and
Clinical Microbiology and Infection | 2010
Rebecca R. Roberts; E.K. Mensah; Robert A. Weinstein
15,275 for confirmed hospital-acquired infection. The economic model explained 56% of the total variability in cost among patients. Hospitals can use these data when evaluating potential cost savings from effective infection-control measures.
Endocrine Practice | 2009
Ambika Babu; Avinder Mehta; Pilar Guerrero; Zhen Chen; Peter Meyer; Chung Kay Koh; Rebecca R. Roberts; Jeffrey Schaider; Leon Fogelfeld
Background:Hospitals will increasingly bear the costs for healthcare-acquired conditions such as infection. Our goals were to estimate the costs attributable to healthcare-acquired infection (HAI) and conduct a sensitivity analysis comparing analytic methods. Methods:A random sample of high-risk adults hospitalized in the year 2000 was selected. Measurements included total and variable medical costs, length of stay (LOS), HAI site, APACHE III score, antimicrobial resistance, and mortality. Medical costs were measured from the hospital perspective. Analytic methods included ordinary least squares linear regression and median quantile regression, Winsorizing, propensity score case matching, attributable LOS multiplied by mean daily cost, semi-log transformation, and generalized linear modeling. Three-state proportional hazards modeling was also used for LOS estimation. Attributable mortality was estimated using logistic regression. Results:Among 1253 patients, 159 (12.7%) developed HAI. Using different methods, attributable total costs ranged between